ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Friday, November 6, 2020

9:00AM-11:00AM: Abstract Number: 0053

¿Comprende? Assessing the Readability of Freely Available Spanish-Language Online Patient Education Materials for Rheumatologic Diseases

Healthcare Disparities in Rheumatology Poster

9:00AM-11:00AM: Abstract Number: 0090

110 Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) in a Rheumatology Disease Unit: Fracture, Neuropathy, and Pernicious Anemia Are Clues to Recognition

Miscellaneous Rheumatic & Inflammatory Diseases Poster I: Diagnosis and Testing

9:00AM-11:00AM: Abstract Number: 0412

2019 Novel Coronavirus Disease (COVID-19) in Patients with Large-Vessels Vasculitis: Single-centre Experience in Paris

Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

9:00AM-11:00AM: Abstract Number: 0073

A Cross-Species Map of Neutrophil Inflammatory Responses

Innate Immunity Poster

9:00AM-11:00AM: Abstract Number: 0305

A Delphi Consensus Study to Standardize Terminology for the Pre-clinical Phase of Psoriatic Arthritis

Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I: Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 0399

A Heavy Burden of Calcinosis Reflects Cumulative Disease Damage in Scleroderma

Systemic Sclerosis & Related Disorders – Clinical Poster I

9:00AM-11:00AM: Abstract Number: 0106

A Machine Learning-derived Radiomics Nomogram for Diagnosis of Osteoporosis and Osteopenia

Osteoporosis & Metabolic Bone Disease Poster

9:00AM-11:00AM: Abstract Number: 0026

A Modified Version of the 2016 ACR Fibromyalgia Criteria Cognitive Items Results in Stronger Correlation Between Subjective and Objective Measures of Cognitive Impairment

Fibromyalgia & Other Clinical Pain Syndromes Poster

9:00AM-11:00AM: Abstract Number: 0201

A Multicenter, Randomized, Placebo-controlled, Double-blind Phase 2 Study of SHR0302 versus Placebo in Chinese Subjects with Moderate to Severe Active Rheumatoid Arthritis (RA)

RA – Treatments Poster I: RA Treatments & Their Safety

9:00AM-11:00AM: Abstract Number: 0199

A Phase 1, Randomized, Open-label, Parallel Group, Single-dose Study to Compare the Pharmacokinetics and Safety of the Auto-injector and Pre-filled Syringe of CT-P17, a Proposed, Higher Concentration Biosimilar (100 mg/mL) Adalimumab, in Healthy Subjects

RA – Treatments Poster I: RA Treatments & Their Safety

9:00AM-11:00AM: Abstract Number: 0385

A Pilot Study to Evaluate the Safety and Efficacy of Treprostinil in the Treatment of Calcinosis in Patients with Systemic Sclerosis

Systemic Sclerosis & Related Disorders – Clinical Poster I

9:00AM-11:00AM: Abstract Number: 0241

A Prospective Analysis of Factors Impacting Medication Adverse Events in Patients with Rheumatoid Arthritis

RA – Treatments Poster I: RA Treatments & Their Safety

9:00AM-11:00AM: Abstract Number: 0198

A Prospective Cohort Study of Vehicle Control as a Measure of Driving Performance in Patients with Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster I: Multimorbidity

9:00AM-11:00AM: Abstract Number: 0032

A Prospective, Multicenter, Clinical Performance Evaluation Study for an in-vitro Diagnostics Medical Device (PREDYSTIC® Infliximab RA) for Prediction of Infliximab Responsiveness in the Treatment of Rheumatoid Arthritis

Genetics, Genomics & Proteomics Poster

9:00AM-11:00AM: Abstract Number: 0125

A Resident-Led Interdisciplinary Quality Improvement Initiative to Increase Osteoporosis Screening in an Urban Clinic

Osteoporosis & Metabolic Bone Disease Poster

1
2
3
…
35
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].